Abstract
Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.
| Original language | English |
|---|---|
| Pages (from-to) | 307-317 |
| Number of pages | 11 |
| Journal | Alzheimer's and Dementia |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2023 |
Keywords
- Alzheimer's disease
- amyloid
- cerebrovascular disease
- digital biomarkers
- generalizability
- mild cognitive impairment
- plasma biomarkers
- tau
- underrepresented populations